Name | Number of supported studies | Average coverage | |
---|---|---|---|
hepatocyte | 5 studies | 36% ± 14% |
Insufficient scRNA-seq data for expression of HRG at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 57386.77 | 226 / 226 | 96% | 996.17 | 388 / 406 |
kidney | 100% | 575.84 | 89 / 89 | 5% | 3.15 | 45 / 901 |
skin | 63% | 10.08 | 1146 / 1809 | 2% | 0.07 | 9 / 472 |
peripheral blood | 51% | 207.01 | 473 / 929 | 0% | 0 | 0 / 0 |
pancreas | 43% | 4.11 | 140 / 328 | 7% | 0.15 | 12 / 178 |
lung | 43% | 7.60 | 248 / 578 | 5% | 0.17 | 59 / 1155 |
esophagus | 40% | 4.48 | 583 / 1445 | 4% | 0.06 | 7 / 183 |
spleen | 42% | 37.46 | 102 / 241 | 0% | 0 | 0 / 0 |
adrenal gland | 41% | 4.17 | 106 / 258 | 1% | 0.04 | 2 / 230 |
thymus | 41% | 4.70 | 266 / 653 | 0% | 0.01 | 3 / 605 |
ovary | 36% | 3.36 | 64 / 180 | 4% | 0.11 | 18 / 430 |
stomach | 36% | 3.19 | 130 / 359 | 1% | 0.01 | 2 / 286 |
prostate | 33% | 2.52 | 82 / 245 | 1% | 0.02 | 7 / 502 |
uterus | 32% | 3.46 | 54 / 170 | 2% | 0.06 | 10 / 459 |
brain | 33% | 3.05 | 883 / 2642 | 0% | 0 | 0 / 705 |
heart | 30% | 4.78 | 259 / 861 | 0% | 0 | 0 / 0 |
intestine | 26% | 3.22 | 249 / 966 | 2% | 2.16 | 11 / 527 |
bladder | 24% | 1.19 | 5 / 21 | 2% | 0.08 | 10 / 504 |
adipose | 25% | 5.46 | 299 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 25% | 3.02 | 330 / 1335 | 0% | 0 | 0 / 0 |
breast | 24% | 7.73 | 108 / 459 | 1% | 0.02 | 7 / 1118 |
muscle | 19% | 1.49 | 149 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 3% | 0.04 | 1 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0001525 | Biological process | angiogenesis |
GO_0010468 | Biological process | regulation of gene expression |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_0050832 | Biological process | defense response to fungus |
GO_2001027 | Biological process | negative regulation of endothelial cell chemotaxis |
GO_0010951 | Biological process | negative regulation of endopeptidase activity |
GO_0010543 | Biological process | regulation of platelet activation |
GO_0002839 | Biological process | positive regulation of immune response to tumor cell |
GO_0051918 | Biological process | negative regulation of fibrinolysis |
GO_0007162 | Biological process | negative regulation of cell adhesion |
GO_0006935 | Biological process | chemotaxis |
GO_0033629 | Biological process | negative regulation of cell adhesion mediated by integrin |
GO_0051838 | Biological process | cytolysis by host of symbiont cells |
GO_0042730 | Biological process | fibrinolysis |
GO_0043537 | Biological process | negative regulation of blood vessel endothelial cell migration |
GO_0030168 | Biological process | platelet activation |
GO_0016525 | Biological process | negative regulation of angiogenesis |
GO_0010593 | Biological process | negative regulation of lamellipodium assembly |
GO_0030193 | Biological process | regulation of blood coagulation |
GO_0050730 | Biological process | regulation of peptidyl-tyrosine phosphorylation |
GO_0051894 | Biological process | positive regulation of focal adhesion assembly |
GO_1900747 | Biological process | negative regulation of vascular endothelial growth factor signaling pathway |
GO_0043254 | Biological process | regulation of protein-containing complex assembly |
GO_0061844 | Biological process | antimicrobial humoral immune response mediated by antimicrobial peptide |
GO_2000504 | Biological process | positive regulation of blood vessel remodeling |
GO_0043065 | Biological process | positive regulation of apoptotic process |
GO_0032956 | Biological process | regulation of actin cytoskeleton organization |
GO_0030308 | Biological process | negative regulation of cell growth |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0062023 | Cellular component | collagen-containing extracellular matrix |
GO_0072562 | Cellular component | blood microparticle |
GO_0009986 | Cellular component | cell surface |
GO_0031093 | Cellular component | platelet alpha granule lumen |
GO_0004869 | Molecular function | cysteine-type endopeptidase inhibitor activity |
GO_0008201 | Molecular function | heparin binding |
GO_0019865 | Molecular function | immunoglobulin binding |
GO_0004867 | Molecular function | serine-type endopeptidase inhibitor activity |
GO_0005102 | Molecular function | signaling receptor binding |
GO_0020037 | Molecular function | heme binding |
GO_0008270 | Molecular function | zinc ion binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0043395 | Molecular function | heparan sulfate proteoglycan binding |
GO_0005515 | Molecular function | protein binding |
Gene name | HRG |
Protein name | Histidine-rich glycoprotein (Histidine-proline-rich glycoprotein) (HPRG) |
Synonyms | |
Description | FUNCTION: Plasma glycoprotein that binds a number of ligands such as heme, heparin, heparan sulfate, thrombospondin, plasminogen, and divalent metal ions. Binds heparin and heparin/glycosaminoglycans in a zinc-dependent manner. Binds heparan sulfate on the surface of liver, lung, kidney and heart endothelial cells. Binds to N-sulfated polysaccharide chains on the surface of liver endothelial cells. Inhibits rosette formation. Acts as an adapter protein and is implicated in regulating many processes such as immune complex and pathogen clearance, cell chemotaxis, cell adhesion, angiogenesis, coagulation and fibrinolysis. Mediates clearance of necrotic cells through enhancing the phagocytosis of necrotic cells in a heparan sulfate-dependent pathway. This process can be regulated by the presence of certain HRG ligands such as heparin and zinc ions. Binds to IgG subclasses of immunoglobins containing kappa and lambda light chains with different affinities regulating their clearance and inhibiting the formation of insoluble immune complexes. Tethers plasminogen to the cell surface. Binds T-cells and alters the cell morphology. Modulates angiogenesis by blocking the CD6-mediated antiangiongenic effect of thrombospondins, THBS1 and THBS2. Acts as a regulator of the vascular endothelial growth factor (VEGF) signaling pathway; inhibits endothelial cell motility by reducing VEGF-induced complex formation between PXN/paxillin and ILK/integrin-linked protein kinase and by promoting inhibition of VEGF-induced tyrosine phosphorylation of focal adhesion kinases and alpha-actinins in endothelial cells. Also plays a role in the regulation of tumor angiogenesis and tumor immune surveillance. Normalizes tumor vessels and promotes antitumor immunity by polarizing tumor-associated macrophages, leading to decreased tumor growth and metastasis. . |
Accessions | P04196 ENST00000232003.5 |